Literature DB >> 17670815

Incorporation of high levels of chimeric human immunodeficiency virus envelope glycoproteins into virus-like particles.

Bao-Zhong Wang1, Weimin Liu, Sang-Moo Kang, Munir Alam, Chunzi Huang, Ling Ye, Yuliang Sun, Yingying Li, Denise L Kothe, Peter Pushko, Terje Dokland, Barton F Haynes, Gale Smith, Beatrice H Hahn, Richard W Compans.   

Abstract

The human immunodeficiency virus (HIV) envelope (Env) protein is incorporated into HIV virions or virus-like particles (VLPs) at very low levels compared to the glycoproteins of most other enveloped viruses. To test factors that influence HIV Env particle incorporation, we generated a series of chimeric gene constructs in which the coding sequences for the signal peptide (SP), transmembrane (TM), and cytoplasmic tail (CT) domains of HIV-1 Env were replaced with those of other viral or cellular proteins individually or in combination. All constructs tested were derived from HIV type 1 (HIV-1) Con-S DeltaCFI gp145, which itself was found to be incorporated into VLPs much more efficiently than full-length Con-S Env. Substitution of the SP from the honeybee protein mellitin resulted in threefold-higher chimeric HIV-1 Env expression levels on insect cell surfaces and an increase of Env incorporation into VLPs. Substitution of the HIV TM-CT with sequences derived from the mouse mammary tumor virus (MMTV) envelope glycoprotein, influenza virus hemagglutinin, or baculovirus (BV) gp64, but not from Lassa fever virus glycoprotein, was found to enhance Env incorporation into VLPs. The highest level of Env incorporation into VLPs was observed in chimeric constructs containing the MMTV and BV gp64 TM-CT domains in which the Gag/Env molar ratios were estimated to be 4:1 and 5:1, respectively, compared to a 56:1 ratio for full-length Con-S gp160. Electron microscopy revealed that VLPs with chimeric HIV Env were similar to HIV-1 virions in morphology and size and contained a prominent layer of Env spikes on their surfaces. HIV Env specific monoclonal antibody binding results showed that chimeric Env-containing VLPs retained conserved epitopes and underwent conformational changes upon CD4 binding.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17670815      PMCID: PMC2045522          DOI: 10.1128/JVI.00542-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

Review 1.  Viral late domains.

Authors:  Eric O Freed
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

2.  Structural components of mouse mammary tumor virus. I. Polypeptides of the virion.

Authors:  M J Yagi; R W Compans
Journal:  Virology       Date:  1977-02       Impact factor: 3.616

3.  Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein.

Authors:  L A Lasky; J E Groopman; C W Fennie; P M Benz; D J Capon; D J Dowbenko; G R Nakamura; W M Nunes; M E Renz; P W Berman
Journal:  Science       Date:  1986-07-11       Impact factor: 47.728

4.  Site-directed mutagenesis by overlap extension using the polymerase chain reaction.

Authors:  S N Ho; H D Hunt; R M Horton; J K Pullen; L R Pease
Journal:  Gene       Date:  1989-04-15       Impact factor: 3.688

5.  Influenza virus proteins. I. Analysis of polypeptides of the virion and identification of spike glycoproteins.

Authors:  R W Compans; H D Klenk; L A Caliguiri; P W Choppin
Journal:  Virology       Date:  1970-12       Impact factor: 3.616

6.  Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus.

Authors:  Elena Chertova; Julian W Bess; Bruce J Crise; Raymond C Sowder II; Terra M Schaden; Joanne M Hilburn; James A Hoxie; Raoul E Benveniste; Jeffrey D Lifson; Louis E Henderson; Larry O Arthur
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

7.  Expression of the HTLV-III envelope gene by a recombinant vaccinia virus.

Authors:  S Chakrabarti; M Robert-Guroff; F Wong-Staal; R C Gallo; B Moss
Journal:  Nature       Date:  1986 Apr 10-16       Impact factor: 49.962

8.  Genetics of mouse mammary tumor virus-induced mammary tumors: linkage of tumor induction to the gag gene.

Authors:  L M Hook; Y Agafonova; S R Ross; S J Turner; T V Golovkina
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

9.  Antigenicity and immunogenicity of domains of the human immunodeficiency virus (HIV) envelope polypeptide expressed in the yeast Saccharomyces cerevisiae.

Authors:  P J Barr; K S Steimer; E A Sabin; D Parkes; C George-Nascimento; J C Stephans; M A Powers; A Gyenes; G A Van Nest; E T Miller
Journal:  Vaccine       Date:  1987-06       Impact factor: 3.641

10.  Production and characterization of simian--human immunodeficiency virus-like particles.

Authors:  Q Yao; F M Kuhlmann; R Eller; R W Compans; C Chen
Journal:  AIDS Res Hum Retroviruses       Date:  2000-02-10       Impact factor: 2.205

View more
  43 in total

1.  Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations.

Authors:  Anne-Marie C Andersson; Emeline Ragonnaud; Kelly E Seaton; Sheetal Sawant; Antonella Folgori; Stefano Colloca; Celia Labranche; David C Montefiori; Georgia D Tomaras; Peter J Holst
Journal:  Vaccine       Date:  2016-09-12       Impact factor: 3.641

2.  Inhibition of envelope-mediated CD4+-T-cell depletion by human immunodeficiency virus attachment inhibitors.

Authors:  Louis Alexander; Sharon Zhang; Brian McAuliffe; David Connors; Nannon Zhou; Tao Wang; Michele Agler; John Kadow; Pin-Fang Lin
Journal:  Antimicrob Agents Chemother       Date:  2009-08-31       Impact factor: 5.191

3.  Dense Array of Spikes on HIV-1 Virion Particles.

Authors:  Armando Stano; Daniel P Leaman; Arthur S Kim; Lei Zhang; Ludovic Autin; Jidnyasa Ingale; Syna K Gift; Jared Truong; Richard T Wyatt; Arthur J Olson; Michael B Zwick
Journal:  J Virol       Date:  2017-06-26       Impact factor: 5.103

4.  Virus-like particles presenting flagellin exhibit unique adjuvant effects on eliciting T helper type 1 humoral and cellular immune responses to poor immunogenic influenza virus M2e protein vaccine.

Authors:  Ki-Hye Kim; Young-Man Kwon; Young-Tae Lee; Hye Suk Hwang; Min-Chul Kim; Eun-Ju Ko; Bao-Zhong Wang; Fu-Shi Quan; Sang-Moo Kang
Journal:  Virology       Date:  2018-09-07       Impact factor: 3.616

5.  Co-delivery of GPI-anchored CCL28 and influenza HA in chimeric virus-like particles induces cross-protective immunity against H3N2 viruses.

Authors:  Teena Mohan; Jongrok Kim; Zachary Berman; Shelly Wang; Richard W Compans; Bao-Zhong Wang
Journal:  J Control Release       Date:  2016-05-10       Impact factor: 9.776

6.  Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus.

Authors:  Min-Chul Kim; Jae-Min Song; Eunju O; Young-Man Kwon; Youn-Jeong Lee; Richard W Compans; Sang-Moo Kang
Journal:  Mol Ther       Date:  2012-12-18       Impact factor: 11.454

7.  Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin.

Authors:  William C Weldon; Bao-Zhong Wang; Maria P Martin; Dimitrios G Koutsonanos; Ioanna Skountzou; Richard W Compans
Journal:  PLoS One       Date:  2010-09-01       Impact factor: 3.240

8.  Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses.

Authors:  Bao-Zhong Wang; Fu-Shi Quan; Sang-Moo Kang; Jadranka Bozja; Ioanna Skountzou; Richard W Compans
Journal:  J Virol       Date:  2008-09-10       Impact factor: 5.103

Review 9.  Virus-like particles as universal influenza vaccines.

Authors:  Sang-Moo Kang; Min-Chul Kim; Richard W Compans
Journal:  Expert Rev Vaccines       Date:  2012-08       Impact factor: 5.217

Review 10.  Influenza vaccines based on virus-like particles.

Authors:  Sang-Moo Kang; Jae-Min Song; Fu-Shi Quan; Richard W Compans
Journal:  Virus Res       Date:  2009-04-15       Impact factor: 3.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.